Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database

• Published in: PLOS ONE Vol. 18; no. 4; p. e0283931
• Main Authors: Handa, Hiroshi, Ishida, Tadao, Ozaki, Shuji, Mori, Asuka, Kato, Kenichi, Iida, Shinsuke
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science (PLoS) 06.04.2023; Public Library of Science
• Subjects: Age; Aged; Antimitotic agents; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bortezomib; Care and treatment; Clinical outcomes; Data analysis; Dexamethasone; Diagnosis; Disease; Drugs; Health services; Humans; Immunosuppressive agents; Immunotherapy; Induction therapy; Information management; Inhibitor drugs; Insurance claims; Japan; Lenalidomide; Lenalidomide - therapeutic use; Medical advice systems; Medical diagnosis; Medicine; Medicine and Health Sciences; Multiple Myeloma; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; Patient outcomes; Patients; People and Places; Q; R; Research Article; Science; Statistics; Stem cell transplantation; Stem cells; Targeted cancer therapy; Therapy; Transplantation; Vision; Japan; Asia
• DOI: 10.1371/journal.pone.0283931
• ISSN: 1932-6203

Multiple myeloma therapy has made remarkable progress with the advent of new drugs. We explored the treatment pattern and outcomes in Japanese patients with multiple myeloma using the Medical Data Vision database. Patients were categorized as per the initial diagnosis period (2003–2015 and 2016–2020), considering the adoption of these new agents and then based on stem cell transplantation. Overall, 6438 patient data were extracted as eligible for data analysis, and the median age at the index diagnosis date was 72.0 years. Bortezomib/dexamethasone was the most common regimen for induction therapy in patients requiring stem cell transplantation from 2003–2015, and the use of bortezomib/lenalidomide/dexamethasone increased from 2016–2020. Lenalidomide/dexamethasone was the most commonly used post-transplant therapy. In the non-stem cell transplantation group, bortezomib/dexamethasone was mainly used for both periods, while lenalidomide/dexamethasone was primarily used from 2016–2020. There was a trend toward shorter first-line treatment duration and a shift to additional treatment patterns with new drugs at the following lines. The time to inpatient death period suggested an improvement between the two periods. Thus, this study revealed that recent diversification of treatment options is preferred and contributes to improved outcomes in the clinical practice of multiple myeloma in Japan.